ArticleActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2025
Office-based transnasal injection laryngoplasty with cross linked hyaluronic acid in unilateral vocal fold palsy: long-term results.
Article in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess long-term phonatory outcomes of office-based injection laryngoplasty with cross-linked hyaluronic acid (HA) via transnasal flexible endoscopic phonosurgery (FEPS), followed by voice therapy, in patients with unilateral vocal fold palsy (UVFP). Methods: Retrospective study on 20 UVFP patients treated with HA via FEPS within 6 months from diagnosis. All underwent postoperative voice rehabilitation. Voice outcomes were assessed at baseline (T0), and at 3 (T1), 12 (T2), and 24 (T3) months using Maximum phonation time (MPT), Cepstral Peak Prominence Smoothed (CPPS), Acoustic Voice Quality Index (AVQI), GRBAS rating scale, and Voice Handicap Index-10 (VHI-10). Results: MPT, CPPS, and AVQI improved significantly at T1, remaining stable at T2 and T3. GRBAS scores showed marked improvement at T3. Videolaryngostroboscopy confirmed better glottic closure and vocal fold vibration. VHI-10 scores decreased consistently, indicating reduced voice handicap. Conclusions: FEPS-guided HA injection is a safe, effective, and minimally invasive treatment for UVFP, ensuring lasting voice improvements, especially when performed early and combined with voice therapy. This strategy may reduce the need for open surgery in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.